Ensign Peak Advisors, Inc Phathom Pharmaceuticals, Inc. Transaction History

Ensign Peak Advisors, Inc

$51.2 Billion
Q1 2025

A detailed history of Ensign Peak Advisors, Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 2,514,284 shares of PHAT stock, worth $10.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,514,284

Previous 2,527,054 0.51%

Holding current value

$10.9 Million

Previous $20.5 Million 23.17%

% of portfolio

0.03%

Previous 0.04%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$4.22 - $7.74 $53,889 - $98,839	-12,770 Reduced 0.51%	2,514,284 $15.8 Million
Q4 2024 Feb 13, 2025	SELL	$7.45 - $18.94 $404,788 - $1.03 Million	-54,334 Reduced 2.1%	2,527,054 $20.5 Million
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $3.45 Million - $6.56 Million	336,560 Added 14.99%	2,581,388 $46.7 Million
Q2 2024 Aug 13, 2024	SELL	$8.97 - $12.05 $315,492 - $423,822	-35,172 Reduced 1.54%	2,244,828 $23.1 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $3.83 Million - $5.87 Million	547,828 Added 31.63%	2,280,000 $20.8 Million
Q3 2023 Nov 13, 2023	SELL	$10.26 - $15.7 $256,038 - $391,793	-24,955 Reduced 1.42%	1,732,172 $18 Million
Q2 2023 Aug 14, 2023	SELL	$7.28 - $14.32 $29,585 - $58,196	-4,064 Reduced 0.23%	1,757,127 $25.2 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $553,641 - $1.04 Million	85,703 Added 5.12%	1,761,191 $19.5 Million
Q2 2022 Aug 12, 2022	BUY	$6.2 - $15.5 $3.54 Million - $8.85 Million	570,729 Added 51.66%	1,675,488 $14.1 Million
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $2.44 Million - $4.23 Million	-210,958 Reduced 16.03%	1,104,759 $15 Million
Q4 2021 Feb 11, 2022	BUY	$17.83 - $33.15 $2.59 Million - $4.82 Million	145,493 Added 12.43%	1,315,717 $25.9 Million
Q3 2021 Nov 12, 2021	SELL	$30.69 - $36.83 $1.53 Million - $1.83 Million	-49,786 Reduced 4.08%	1,170,224 $37.6 Million
Q2 2021 Aug 13, 2021	SELL	$32.66 - $39.87 $635,302 - $775,551	-19,452 Reduced 1.57%	1,220,010 $41.3 Million
Q1 2021 May 12, 2021	BUY	$33.86 - $48.68 $504,852 - $725,818	14,910 Added 1.22%	1,239,462 $46.6 Million
Q4 2020 Feb 12, 2021	BUY	$33.22 - $50.26 $11 Million - $16.7 Million	331,760 Added 37.16%	1,224,552 $40.7 Million
Q3 2020 Nov 12, 2020	BUY	$29.24 - $40.19 $1.25 Million - $1.72 Million	42,789 Added 5.03%	892,792 $32.7 Million
Q2 2020 Aug 12, 2020	BUY	$25.06 - $54.6 $6.33 Million - $13.8 Million	252,511 Added 42.26%	850,003 $28 Million
Q1 2020 May 11, 2020	SELL	$24.65 - $42.83 $477,347 - $829,402	-19,365 Reduced 3.14%	597,492 $15.4 Million
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $11.5 Million - $23.2 Million	616,857 New	616,857 $19.2 Million

Others Institutions Holding PHAT

# of Institutions

152

Shares Held

66.6M

Call Options Held

94K

Put Options Held

55.5K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $170M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Phathom Pharmaceuticals, Inc. Transaction History